Mechanisms of Action of Hypomethylating Agents: Endogenous Retroelements at the Epicenter
Abnormal DNA methylation patterns are thought to drive the pathobiology of high-risk myelodysplastic syndromes (HR-MDS) and acute myeloid leukemia (AML). Sixteen years after their initial approval, the hypomethylating agents (HMAs), 5-azacytidine (AZA) and 5-aza-2′-deoxycytidine, remain the mainstay...
Main Authors: | Chryssoula Kordella, Eleftheria Lamprianidou, Ioannis Kotsianidis |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-03-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.650473/full |
Similar Items
-
Hypomethylating Chemotherapeutic Agents as Therapy for Myelodysplastic Syndromes and Prevention of Acute Myeloid Leukemia
by: Vincent G. Sorrentino, et al.
Published: (2021-07-01) -
Resistance to Hypomethylating Agents in Myelodysplastic Syndrome and Acute Myeloid Leukemia From Clinical Data and Molecular Mechanism
by: Guangjie Zhao, et al.
Published: (2021-09-01) -
How Azanucleosides Affect Myeloid Cell Fate
by: Anna Stein, et al.
Published: (2022-08-01) -
Hypomethylating Agents (HMAs) as Salvage Therapy in Relapsed or Refractory AML: An Italian Multicentric Retrospective Study
by: Federica Lessi, et al.
Published: (2021-08-01) -
Placental Hypomethylation Is More Pronounced in Genomic Loci Devoid of Retroelements
by: Aniruddha Chatterjee, et al.
Published: (2016-07-01)